ICON plc | Clinical Research Organisation (CRO) for Drug Development

The Role of ICER as an Independent HTA Organisation

Primary research evaluating ICER’s influence over payers and manufactures

Personalising Digital Health Solutions

Digital health solutions for clinical R&D efficiency and patient outcomes

Making Sense of the Biosimilars Market

Insights you need for successful biosimilar commercialisation

Key Considerations in Chronic Pain Clinical Trials

Determine the right design, assessments and endpoints in your pain study

ICON Insights

12 August 2019

Alexa… What’s the deal with voice assistants?

As the buzz around voice technology increases, our digital team is asked more & more, “What’s the deal with voice assistants? Can we offer this to our clients?”

29 July 2019

The Long Journey towards Patient Centricity

Various regulatory efforts have been implemented in the last 25-30 years to include the patients’ perspective into drug development.

29 July 2019

Insights from Inside the Jury Room: 2019 Medical, Marketing & Media (MM&M) Awards

Read our latest blog post to access insights from inside the 2019 Medical Marketing & Media (MM&M) Awards jury room.

22 July 2019

Patient Centricity in Oncology Trials

Adopting patient-centric elements into oncology clinical trials has the potential to significantly impact patient recruitment and retention.

22 July 2019

Pharma Marketing in the Digital Age

Social media and digital technology are providing new opportunities for marketers by facilitating direct interaction with patients and care partners.

10 July 2019

Connecting with the Patient for Better Insights

Getting more connected with the patient and easing their burden is really making a difference to enrollment rates.

08 July 2019

The Need for New Business Models under MDR/IVDR

The new MDR/IVDR will go into effect in 2020, greatly increasing the complexity of keeping existing products on the market and introducing new ones.

05 July 2019

5 Applications of AI to Enhance RWE Generation

Exploring machine learning and natural language processing to maximize RWE output using advanced computing.

17 June 2019

EMA Publishes Second Draft Guideline on New MDR Rules Specifying Quality Requirements for Drug-Device Combinations

Key takeaways from the EMA’s second draft guidance on MDR and its impact on combination products.

Services

Therapeutics

Innovation

Insights

News & Events

About ICON

Flow Cytometry for Driving Trials Forward

Site & Patient Solutions

MDR/IVDR Brings Higher Costs and Bottlenecks

The Impact of AI on Outcomes Based Contracting